GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » EV-to-EBIT

Enveric Biosciences (Enveric Biosciences) EV-to-EBIT : 0.02 (As of Apr. 25, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Enveric Biosciences's Enterprise Value is $-0.42 Mil. Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-18.11 Mil. Therefore, Enveric Biosciences's EV-to-EBIT for today is 0.02.

The historical rank and industry rank for Enveric Biosciences's EV-to-EBIT or its related term are showing as below:

ENVB' s EV-to-EBIT Range Over the Past 10 Years
Min: -509.24   Med: -1.84   Max: 501.95
Current: 0.02

During the past 13 years, the highest EV-to-EBIT of Enveric Biosciences was 501.95. The lowest was -509.24. And the median was -1.84.

ENVB's EV-to-EBIT is ranked better than
97.07% of 444 companies
in the Biotechnology industry
Industry Median: 8.05 vs ENVB: 0.02

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Enveric Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 was $1.27 Mil. Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-18.11 Mil. Enveric Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1,422.81%.


Enveric Biosciences EV-to-EBIT Historical Data

The historical data trend for Enveric Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences EV-to-EBIT Chart

Enveric Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.24 -6.46 -0.23 0.62 -0.07

Enveric Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.45 -0.01 -0.05 -0.07

Competitive Comparison of Enveric Biosciences's EV-to-EBIT

For the Biotechnology subindustry, Enveric Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's EV-to-EBIT falls into.



Enveric Biosciences EV-to-EBIT Calculation

Enveric Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-0.416/-18.114
=0.02

Enveric Biosciences's current Enterprise Value is $-0.42 Mil.
Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enveric Biosciences  (NAS:ENVB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Enveric Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-18.114/1.273116
=-1,422.81 %

Enveric Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 was $1.27 Mil.
Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enveric Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences (Enveric Biosciences) Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Executives
Frank Pasqualone director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney officer: Chief Financial Officer 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey officer: Chief Financial Officer 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil director C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson director 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel officer: Chief Technical Officer 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker director, officer: Chief Executive Officer 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini officer: Chief Scientific Officer 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward officer: Chief Financial Officer 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind director
Marcus Schabacker director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer director 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson director, officer: CEO and Chairman C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins officer: Chief Medical Officer C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103

Enveric Biosciences (Enveric Biosciences) Headlines